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Abstract
The role of non-invasive ventilation (NIV) in acute respiratory failure caused by viral pneumonia remains controversial. Our objective
was to evaluate the use of NIV in a cohort of (H1N1)v pneumonia. Usefulness and success of NIV were assessed in a prospective,
observational registry of patients with inﬂuenza A (H1N1) virus pneumonia in 148 Spanish intensive care units (ICUs) in 2009–10. Signif-
icant variables for NIV success were included in a multivariate analysis. In all, 685 patients with conﬁrmed inﬂuenza A (H1N1)v viral
pneumonia were admitted to participating ICUs; 489 were ventilated, 177 with NIV. The NIV was successful in 72 patients (40.7%), the
rest required intubation. Low Acute Physiology and Chronic Health Evaluation (APACHE) II, low Sequential Organ Failure Assessment
(SOFA) and absence of renal failure were associated with NIV success. Success of NIV was independently associated with fewer than
two chest X-ray quadrant opacities (OR 3.5) and no vasopressor requirement (OR 8.1). However, among patients with two or more
quadrant opacities, a SOFA score £7 presented a higher success rate than those with SOFA score >7 (OR 10.7). Patients in whom NIV
was successful required shorter ventilation time, shorter ICU stay and hospital stay than NIV failure. In patients in whom NIV failed,
the delay in intubation did not increase mortality (26.5% versus 24.2%). Clinicians used NIV in 25.8% of inﬂuenza A (H1N1)v viral pneu-
monia admitted to ICU, and treatment was effective in 40.6% of them. NIV success was associated with shorter hospital stay and mor-
tality similar to non-ventilated patients. NIV failure was associated with a mortality similar to those who were intubated from the start.
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Introduction
In the last decade, two viral pandemics have had a signiﬁcant
impact on worldwide health, resulting mainly in severe acute
respiratory failure (ARF). The ﬁrst was the Severe Acute
Respiratory Syndrome (or SARS) in 2003 [1], a virulent clini-
cal entity with a high mortality rate; the second was inﬂuenza
A (H1N1)v [2–6] in 2009, which, according to the WHO
report, caused more than 18 000 deaths within the ﬁrst
season.
The use of non-invasive ventilation (NIV) in adults has
proved effective in treating chronic obstructive pulmonary
disease exacerbation, cardiogenic pulmonary oedema, and
ARF in immunocompromised patients [7]. In these patients,
NIV has achieved signiﬁcant reductions in the rate of endotra-
cheal intubation and ventilator-associated complications, and
has improved survival rates. Nevertheless, some meta-analy-
ses argue against the use of NIV in ARF, because it offers no
advantages over conventional ventilation [7,8]; moreover,
delaying intubation in hypoxaemic intubated patients with
pneumonia may increase the risk of complications [9,10].
Early use of NIV in ARDS caused by viral pneumonia is con-
troversial. We tried to assess when clinicians used this tech-
nique and whether it was successful, performing a secondary
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analysis of the GTEI/SEMICYUC (Grupo de Trabajo de Enfer-
medades Infecciosas/Sociedad Espan˜ola de Medicina Intensiva,
Crı´tica y Unidades Coronarias) Registry, a large cohort of
patients admitted to intensive care units (ICUs) for respira-
tory failure caused by 2009 pandemic inﬂuenza A (H1N1)v
pneumonia. Secondary objectives were to assess if NIV use
might increase mortality if intubation was subsequently
required and if in some patients NIV could be predicted to be
more successful. We hypothesized that the use of NIV in
patients with ARF because of pandemic viral pneumonia might
be effective in some cases and might avoid the need for inva-
sive mechanical ventilation.
Material and Methods
Data for this study were obtained from a voluntary registry
created by node 18 (Director: Jordi Rello) of CIBERES (PCI
Neumonia) and recruited by investigators of the GTEI/
SEMICYUC Study Group (Coordinator: Rafael Zaragoza), in
2009–10. Inclusion criteria were: adult viral pneumonia
patients aged over 18 years, febrile (>38C) acute illness;
respiratory symptoms such as cough, sore throat, myalgia or
inﬂuenza-like illness; ARF (conventional oxygen therapy ‡0.5
to maintain SpO2 ‡92%) requiring ICU admission; and micro-
biological conﬁrmation of 2009 pandemic inﬂuenza A
(H1N1)v by real-time PCR. Data were reported by the
attending physician reviewing medical charts and radiological
and laboratory records within the ﬁrst 12 h after ICU admis-
sion. Patients with exacerbations of chronic obstructive pul-
monary disease, acute pulmonary oedema, acute asthma and
those already intubated at ICU admission or using NIV for
palliative use or rescue therapy were excluded from the
analysis [11]. The study was approved [11] by the institu-
tional review board of Joan XXIII University Hospital, Tar-
ragona (Spain). Patient identiﬁcation remained anonymous
and the requirement for informed consent was waived
because of the observational nature of the study. The ICU
admission criteria and treatment decisions for all patients,
including determination of the need for intubation and type
of antibiotic and antiviral therapy administered, were not
standardized and were made by the attending physician.
Nasopharyngeal-swab specimens were collected at admis-
sion and respiratory secretions were also obtained in intu-
bated patients. Reverse transcription-PCR testing was
performed in accordance with the CDC protocol (http://
www.cdc.gov/h1n1ﬂu/guidance). H1N1 testing was per-
formed at each institution, or centralized in a reference labo-
ratory when not available. A ‘conﬁrmed case’ was deﬁned as
an acute respiratory illness with laboratory-conﬁrmed pan-
demic H1N1 virus infection by real-time reverse transcrip-
tion-PCR or viral culture [12]. Only ‘conﬁrmed cases’ were
included in the current study.
The following information was recorded: demographic
data, comorbidities, times of illness onset and hospital admis-
sion, time to ﬁrst dose of antiviral delivery, microbiological
ﬁndings and chest X-ray ﬁndings at ICU admission. Intubation
and mechanical ventilation requirements (invasive and non-
invasive), medical complications during ICU stay and labora-
tory ﬁndings at ICU admission were also recorded. Chronic
obstructive pulmonary disease was deﬁned as a disease state
characterized by the presence of airﬂow limitation because
of chronic bronchitis or emphysema. The airﬂow obstruction
could be accompanied by airway hyper-reactivity and could
be partially reversible [13]. To determine the severity of ill-
ness, the Acute Physiology and Chronic Health Evaluation
(APACHE) II score [14] was recorded in all patients within
24 h of ICU admission. In addition, organ failure was
assessed using the Sequential Organ Failure Assessment
(SOFA) scoring system [15].
Deﬁnition of community-acquired pneumonia was based
on current American Thoracic Society and Infectious Disease
Society of America guidelines [16]. Primary viral pneumonia
was deﬁned in patients in the acute phase of inﬂuenza virus
illness who presented with acute respiratory distress and
unequivocal alveolar opacities with negative respiratory and
blood bacterial cultures. Secondary bacterial pneumonia was
considered in patients with conﬁrmation of inﬂuenza virus
infection who showed recurrence of fever, increase in cough
and production of purulent sputum plus positive bacterial
respiratory or blood cultures [17]. Respiratory cultures were
based on tracheal aspirates obtained immediately after intu-
bation. Acute renal failure was deﬁned as the need for renal
replacement therapy, in accordance with the International
Consensus Conference criteria [18].
We have deﬁned comorbidities as the pathological ante-
cedents of each patient, and antiviral gap as time of delay
between the onset of symptoms and the start of antiviral
treatment. Multiple organ dysfunction syndrome (MODS)
and shock were deﬁned following international criteria
[15,19]. NIV was always used for ARF at an early stage. Fail-
ure of NIV was deﬁned if the patient was intubated and inva-
sively ventilated after an NIV trial (when SpO2 <92% or
important respiratory work appeared).
Data were analysed using SPSS 18.0 software (Chicago, IL,
USA). Data are expressed as frequency (percentage) or med-
ian (25th–75th interquartile range). For univariate analysis of
the qualitative variables, the Chi-squared and Fisher tests were
used. Quantitative variables were analysed by comparison of
means with the Student’s t test. Stepwise multivariate analysis
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was performed with logistic regression taking the variables
which had p values <0.20 in the univariate analysis, or others
with a special clinical interest (chronic obstructive pulmonary
disease or heart failure), as dependent variables. A p value of
0.05 or less was considered to be statistically signiﬁcant.
Results
In all, 685 adults with 2009 pandemic inﬂuenza A viral pneu-
monia were admitted to the ICUs. Fig. 1 shows the distribu-
tion of the study population depending on the ventilation
provided. Baseline characteristics of 177 non-invasively venti-
lated patients, compared with other subgroups, are brieﬂy
described in Table 1. Compared with non-ventilated subjects,
patients with successful NIV presented more comorbidities
(70.8 versus 57%; p <0.05), a higher lactate dehydrogenase
(758 versus 523 U/L; p <0.05) and creatine kianse (307 ver-
sus 133 U/L; p <0.05) levels, as well as longer ICU stay (6
versus 4 days; p <0.05) (Table 1). An NIV trial was successful
in 72 patients (40.7%), but failed in 105 (59.3%), who
required intubation and invasive mechanical ventilation.
Hence, of the 417 patients who underwent intubation, 312
(74.8%) were intubated and ventilated from the beginning,
and 105 (25.2%) were intubated and ventilated after NIV fail-
ure. Therefore, 14.7% of ventilated patients admitted to the
ICU for inﬂuenza A (H1N1)v pneumonia beneﬁted from NIV.
Lower APACHE II score (median 10 versus 14, p <0.001),
lower SOFA score (median 3.5 versus 6, p <0.001), the pres-
ence of fewer than two chest X-ray quadrant opacities, hae-
modynamic stability (analysed as the absence of the need for
vasopressors) and the absence of acute renal failure or
MODS were associated with NIV success (Table 2). These
patients required shorter mechanical ventilation time (median
3 versus 12 days, p <0.001), shorter ICU stay (6 versus
15 days, p <0.001) and shorter hospital stay (11.5 versus
20.5 days, p <0.001) than patients with NIV failure. Multivari-
ate analysis (Table 2) demonstrated that NIV success was
associated with the presence of fewer than two chest X-ray
quadrant opacities (OR 3.59) and no vasopressor require-
ment (OR 8.18). Moreover, when we compared the subset of
non-invasively ventilated patients with two or more quadrant
opacities for those with a SOFA score >7 versus those with a
SOFA £7, the success rate increased from 5.9% to 40% (OR
10.7, 95% CI 1.3–88.6), whereas when the SOFA score was
£3, the success rate became 71% (95% CI 58–84%).
Total paents
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FIG. 1. Patients with inﬂuenza A (H1N1) virus infection admitted to intensive care units. APE, acute pulmonary oedema; COPD, chronic
obstructive pulmonary disease; MV, mechanical ventilation; NIV, non-invasive ventilation; OTI, orotracheal intubation.
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No differences were found comparing invasively ventilated
patients after NIV failure with those initially submitted to
orotracheal intubation and invasively ventilated, with regard
to APACHE II and SOFA scores, radiographic inﬁltrates, pro-
portion of shock or ventilator-associated pneumonia, ICU
and hospital stay or mortality.
To study the possible association of complications with
delay in intubation in NIV failure patients, we compared
these patients intubated because of NIV failure with those in-
tubated at ICU admission but they did not show signiﬁcantly
different rates of ventilator-associated pneumonia (19.2 ver-
sus 11.1%). Over two-thirds of the ventilator-associated
pneumonia episodes (68.8%) were caused by Pseudomonas
aeruginosa (31.1%), Acinetobacter baumannii (24.4%) or methi-
cillin-resistant Staphylococcus aureus (13.3%). Mortality rates
in ICU were similar in patients who failed NIV (26.5%) and
in those who were intubated and invasively ventilated from
the beginning (24.2%) (OR 1.12; 95% CI 0.67–1.88; p 0.64).
Lengths of ICU stay and of hospital stay were also similar in
both groups.
TABLE 1. Baseline characteristics of the patients admitted to intensive care units because of 2009 inﬂuenza A (H1N1)v
pneumonia, comparing non-ventilated with all the groups of ventilated patients
Variables
Non-ventilated
(n = 196)
Non-invasive ventilation
Initially intubated
(n = 312)All (n = 177)
Successful
(n = 72)
Failed
(n = 105)
Gender (male) (%) 56.2 56.5 56.9 56.2 53.4
Age (years) 41 (32–52) 44 (33–53) 45 (34–53) 44 (32–53) 43 (32–52)
APACHE II 9 (6–13) 12 (9–16) 10 (8–14) 14 (10–18.2)* 15 (10–19)
SOFA score 3 (2–4) 4 (3–7) 4 (3–4) 6 (4–8)* 6 (4–9)
Comorbidities (%) 57 74.6 70.8+ 77.1 71.2
MODS (%) 29.1 61 27.8 83.8* 82.7
CXRqo <2 (%) 34.6 46.2 38.8 35.3** 43.2
Shock (%) 8.4 45.2 13.9 66.7* 65.8
Obesity >30% BMI (%) 17.9 31.6 38.9 26.7 21.7
Chronic renal failure (%) 4.2 5.6 2.8 7.6 5.2
Asthma (%) 11.1 10.2 13.9 7.6 8.4
COPD (%) 5.8 13.6 13.9 13.3 11.7
Heart failure (%) 3.2 6.2 8.3 4.8 4.9
Leucocyte count (per mm3) 6250 (3450–10 650) 5400 (3500–8770) 5000 (4000–7975) 6000 (3475–9175) 6215 (3775–10 200)
Platelet count (1000/mm3) 161.5 (117.5–228.3) 156 (121.5–226.5) 158 (115.8–2350) 155 (124–217) 150 (110–201.5)
LDH (U/L) 523(313–829) 781 (441–1116) 758(441–1006)+ 835 (438–1249) 787(458–1136)
CK (U/L) 133 (53–365) 265 (102–580) 307 (105–618)+ 251 (100–572) 22 (95–636)
Serum creatinine (mg/dL) 0.84 (0.6–1) 0.88 (0.61–1.12) 0.8 (0.6–1) 0.9 (0.7–1.2) 0.9 (0.7–1.3)
Antiviral gap (days) 5 (3–7) 4 (2–6) 4 (2–6) 4 (2–6) 5 (3–6)
Oseltamivir treatment (days) 7 (5–10) 10 (7–12.2) 7 (7–10) 10 (7–14)** 11 (10–14)
Steroid treatment (%) 32.3 43.5 36.7 48.5 41.4
Days from symptom onset
to hospital admission
5 (3–6) 4 (3–5) 4 (2–5) 5 (3–6) 4 (3–6)
Days from hospital to ICU admission 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2)
MV days 7 (3–14) 3 (2–6) 12 (5–18.5)* 13 (8–23)
VAP (%) 11.1 0 11.1*** 19.2
ICU days 4 (3–6) 9 (5–17) 6 (3–9) 15 (8–25)* 17 (10–28.2)
Hospital days 9 (7–13) 16 (10–24.2) 11.5 (7–15)+ 20.5(13.7–32.7)* 24 (15–37.5)
In-hospital mortality (%) 2.2 17.3 4.2 26.5* 24.2
Data are expressed as medians (25th–75th interquartile range), or percentage.
APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment scoring at ICU admission; MODS, multiple organ dysfunction syn-
drome; CXRqo, chest X-ray quadrants opacities; BMI, body mass index; COPD, chronic obstructive pulmonary disease; LDH, lactate dehydrogenase; CK, creatine kinase;
MV, mechanical ventilation; VAP, ventilation-associated pneumonia; ICU, intensive care unit.
Comorbidities included obesity >30% BMI, chronic renal failure, asthma, COPD and heart failure, and calculated as the percentage of patients having at least one comorbidity.
All the laboratory parameters are at ICU admission. Antiviral gap: time from symptom onset to start antiviral treatment. Hospital days: from hospital admission to discharge.
+p <0.05 comparing successful NIV with non-ventilated H1N1 pneumonia patients; *p <0.001 (NIV failure versus NIV success); **p <0.01 (NIV failure versus NIV success);
***p <0.05 (NIV failure versus NIV success).
TABLE 2. Univariate and multivariate analysis of the
comorbidities and parameters associated with non-invasive
ventilation success (Total of 177 patients)
Univariate Multivariate
OR 95% CI p value OR 95% CI p value
Comorbidities
Asthma 0.51 0.19–1.36 0.18
COPD 0.95 0.39–2.28 0.91
Heart failure 0.55 0.16–1.87 0.34
Non-chronic
renal failure
2.88 0.59–14.01 0.18
Pregnancy 3.28 0.68–15.65 0.13
BMI <30% 0.57 0.30–1.08 0.08
APACHE <15 2.94 1.26–6.87 <0.05
SOFA <7 15.90 3.51–72.06 <0.01
CXRqo <2 2.89 1.35–6.19 <0.01 3.59 1.15–11.19 <0.05
Haemodynamic
stability
12.4 5.67–27.09 <0.01 8.18 2.07–32.30 <0.01
No MODS 13.45 6.47–27.97 <0.01
Normal renal
function
8.42 1.86–38.09 <0.01
COPD, chronic obstructive pulmonary disease; BMI, body mass index; APACHE
II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ
Failure Assessment scoring at intensive care unit admission; CXRqo, chest
X-ray quadrant opacities; MODS, multiple organ dysfunction syndrome.
Haemodynamic stability analysed as absence of vasopressor requirement.
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Discussion
This is the ﬁrst large multicentre cohort study to suggest that
ARF in some patients with viral 2009 inﬂuenza A (H1N1)
pneumonia may respond to NIV therapy. Patients with only
one radiological quadrant opacity, haemodynamic stability plus
a SOFA score <8, were more likely to have a positive
response to this treatment. Moreover, in patients with NIV
failure, delayed intubation because of a trial of non-invasive
mechanical ventilation did not increase mortality.
The use of NIV by clinicians in this large cohort of
patients with severe acute respiratory infection is provoca-
tive, contrasting with the recommendations in many guide-
lines. Probably based on a previous study during the severe
acute respiratory syndrome pandemic [20], the European
Society of Intensive Care Medicine (ESICM) [21], the British
Thoracic Society and WHO [22] include NIV as a high-risk
procedure for disease transmission in ARF caused by inﬂu-
enza A (H1N1)v, although it has been shown that intubation
is associated with a higher risk of viral particle transmission
during severe acute respiratory syndrome [23]. Nonetheless,
some reports suggest that NIV can be used in the manage-
ment of some speciﬁc clinical cases of respiratory failure
[24,25].
In this cohort, clinicians used NIV in 36.1% of ventilated
patients, corresponding to 25.8% of all patients admitted to
ICUs with inﬂuenza A (H1N1)v pneumonia. These values are
comparable to other series with an average of reported
cases of around 25% [4,5,26,27] ranging from 19% [27] to
40.7% [4] of all ventilated patients, with and without pneu-
monia. Overall, these reports include a total of 158 NIV
patients. Only three of these series [4,5,26], with a total of
94 patients, assessed the efﬁcacy of NIV, reporting it to be
around 25% (ranging from 14.6% [5] to 58.8% [26]). None of
these studies was designed with the purpose of studying only
the role of NIV, so heterogeneity and lack of standardized
criteria to start NIV is obviously a weakness.
Treatment decisions were not standardized and were
made by the attending physician. NIV was performed in sev-
eral patients despite possible contra-indications, i.e. haemo-
dynamic instability and MODS (61% of patients). Indeed, the
multivariate analysis identiﬁed haemodynamic stability and
presentation with chest X-ray opacities in fewer than two
quadrants as independent factors associated with NIV suc-
cess. Although, vasopressor use per se is not an absolute
contra-indication for NIV, data on vasopressor dosage and
lactate levels could have better clariﬁed this aspect. Based on
the severity of illness of several patients undergoing NIV,
one of the main messages of the present study could be that
NIV should not be offered to critically ill patients with acute
respiratory failure complicating H1N1 viral pneumonia and
other severe acute organ failures.
However, a key question is what happens to patients who
fail NIV and must be intubated and invasively ventilated, and
whether the delay is really detrimental to their clinical out-
come. Some studies have reported an increasing risk of com-
plications and worse prognosis in hypoxaemic patients
intubated after NIV failure [9,10,28,29]. In our series, our
comparison of invasively ventilated patients after NIV failure
with those initially intubated and invasively ventilated pre-
sented a similar mortality. We found no differences between
the two populations.
The main limitation of this study was its observational
design. It is a secondary study of a database in which NIV was
not implemented with a standardized protocol. First, no data
were provided on the severity of acute respiratory failure in
the patients included in the study (for instance: respiratory
rate, PaO2/FiO2, PaCO2, pH). It is different to use NIV at an
early stage of respiratory failure (for instance when the PaO2/
FiO2 ratio is <250) or a late stage of ARF in patients present-
ing with intubation criteria. The lack of these data does not
allow comparison of this study with previous studies dealing
with hypoxaemic respiratory failure. Moreover, ICU admis-
sion and intubation criteria were not standardized. Delay time
of intubation after NIV failure was not recorded. For the same
reasons, NIV techniques and ventilation protocols are not
reported. Again, comparison with previous studies is not pos-
sible. In addition, we cannot exclude that the lack of statistical
difference in incidence of ventilator-associated pneumonia
between patients intubated from the beginning (19.2%) and
those intubated after NIV failure (11.1%) is the result of a lack
of power of the current sample size. In patients at risk of fail-
ure with NIV, methods used to optimize NIV are not
reported. Another limitation is the self-reporting by sites,
which introduces the risk of selection bias. Healthcare work-
ers were not prospectively assessed with follow-up serologies
and the safety of the procedure should be investigated.
Although no ofﬁcial notiﬁcation of nosocomially transmitted
cases has been reported using this therapy, the technique
must be applied using the security measures recommended by
the CDC guidelines and many scientiﬁc societies. In spite of
recommendations against its use and these limitations, clini-
cians used NIV in nearly half of this large multicentre cohort,
and in a signiﬁcant proportion it was successful, suggesting
that patients with severe acute respiratory infection can take
beneﬁt from early non-invasive oxygenation techniques. A
randomized clinical trial is warranted to determine which
patients may beneﬁt from these techniques, to improve prog-
nosis and to help reduce healthcare costs.
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In conclusion, clinicians used NIV in 25.8% of patients with
inﬂuenza A (H1N1)v viral pneumonia admitted to ICU and
treatment was effective in 40.6% of them. NIV was successful
in patients who presented with fewer than two chest X-ray
opacities with haemodynamic stability and SOFA score £7.
NIV failure was associated with a mortality similar to that in
patients who were intubated from the start.
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